SGX To Focus On BCR-ABL Partnership After Discontinuing Troxatyl Trial
This article was originally published in The Pink Sheet Daily
Phase II/III trial in AML patients halted due to low response rates, but SGX says it will focus on a collaboration with Novartis.
You may also be interested in...
CEO Grey acknowledges setback but points to second MET inhibitor and Novartis-partnered BCR-ABL inhibitor program as promising.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.